Progressive Podocyte Injury and Globotriaosylceramide (GL-3) Accumulation in Young Patients with Fabry Disease

Overview

Journal Kidney Int

Publisher Elsevier

Specialty Nephrology

Date 2010 Dec 17

PMID 21160462

Citations 80

Authors

Behzad Najafian

Einar Svarstad

Leif Bostad

Marie-Claire Gubler

Camilla Tondel

Chester Whitley

Michael Mauer

Affiliations

Soon will be listed here.

Abstract

Progressive renal failure often complicates Fabry disease, the pathogenesis of which is not well understood. To further explore this we applied unbiased stereological quantitative methods to electron microscopic changes of Fabry nephropathy and the relationship between parameters of glomerular structure and renal function in 14 young Fabry patients (median age 12 years). Renal biopsies were obtained shortly before enzyme replacement therapy from these patients and from nine normal living kidney donors as controls. Podocyte globotriaosylceramide (GL-3) inclusion volume density increased progressively with age; however, there were no significant relationships between age and endothelial or mesangial inclusion volume densities. Foot process width, greater in male Fabry patients, also progressively increased with age compared with the controls, and correlated directly with proteinuria. In comparison to the biopsies of the controls, endothelial fenestration was reduced in Fabry patients. Thus, our study found relationships between quantitative parameters of glomerular structure in Fabry nephropathy and age, as well as urinary protein excretion. Hence, podocyte injury may play a pivotal role in the development and progression of Fabry nephropathy.

Citing Articles

Anderson-Fabry Disease: Focus on Ophthalmological Implications.

Giovannetti F, DAndrea M, Bracci F, Frustaci A, Chimenti C, Mangiantini P Life (Basel). 2025; 14(12.

PMID: 39768240 PMC: 11676308. DOI: 10.3390/life14121531.

Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease.

Tomsen-Melero J, Molto-Abad M, Merlo-Mas J, Diaz-Riascos Z, Cristobal-Lecina E, Soldevila A Sci Adv. 2024; 10(50):eadq4738.

PMID: 39671483 PMC: 11801267. DOI: 10.1126/sciadv.adq4738.

No differences in native T1 of the renal cortex between Fabry disease patients and healthy subjects in cardiac-dedicated native T1 maps.

Damlin A, Kjellberg F, Themudo R, Chow K, Engblom H, Oscarson M J Cardiovasc Magn Reson. 2024; 26(2):101104.

PMID: 39332708 PMC: 11647495. DOI: 10.1016/j.jocmr.2024.101104.

Reduction in kidney function decline and risk of severe clinical events in agalsidase beta-treated Fabry disease patients: a matched analysis from the Fabry Registry.

Batista J, Hariri A, Maski M, Richards S, Gudivada B, Raynor L Clin Kidney J. 2024; 17(8):sfae194.

PMID: 39139182 PMC: 11320591. DOI: 10.1093/ckj/sfae194.

The role of podocyte injury in the pathogenesis of Fabry disease nephropathy.

Monte Neto J, Mastroianni Kirsztajn G J Bras Nefrol. 2024; 46(3):e20240035.

PMID: 39058283 PMC: 11287863. DOI: 10.1590/2175-8239-JBN-2024-0035en.

References

Meikle P, Ranieri E, Ravenscroft E, Hua C, Brooks D, Hopwood J . Newborn screening for lysosomal storage disorders. Southeast Asian J Trop Med Public Health. 2001; 30 Suppl 2:104-10. View

Macdermot K, Holmes A, Miners A . Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet. 2001; 38(11):769-75. PMC: 1734754. DOI: 10.1136/jmg.38.11.769. View

Elleder M, Poupetova H, Kozich V . [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I]. Cesk Patol. 1998; 34(1):7-12. View

Shu L, Park J, Byun J, Pennathur S, Kollmeyer J, Shayman J . Decreased nitric oxide bioavailability in a mouse model of Fabry disease. J Am Soc Nephrol. 2009; 20(9):1975-85. PMC: 2736776. DOI: 10.1681/ASN.2008111190. View

Desbois J, Maziere J, Gubler M, Allaneau C, Verhaeghe M, HERRAULT A . [Fabry's disease in children. Clinical and biological study of one family. Structure and ultrastructure of the kidney in a hemizygote and a heterozygote]. Ann Pediatr (Paris). 1977; 24(8-9):575-86. View

Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady R . Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol. 2007; 18(5):1576-83. PMC: 1978101. DOI: 10.1681/ASN.2006111263. View

Caramori M, Basgen J, Mauer M . Glomerular structure in the normal human kidney: differences between living and cadaver donors. J Am Soc Nephrol. 2003; 14(7):1901-3. DOI: 10.1097/01.asn.0000075554.31464.da. View

Schiffmann R, Warnock D, Banikazemi M, Bultas J, Linthorst G, Packman S . Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant. 2009; 24(7):2102-11. PMC: 2698092. DOI: 10.1093/ndt/gfp031. View

Kriz W, Gretz N, Lemley K . Progression of glomerular diseases: is the podocyte the culprit?. Kidney Int. 1998; 54(3):687-97. DOI: 10.1046/j.1523-1755.1998.00044.x. View

10.

Schiffmann R, Ries M, Timmons M, Flaherty J, Brady R . Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2005; 21(2):345-54. DOI: 10.1093/ndt/gfi152. View

11.

Torbjornsdotter T, Perrin N, Jaremko G, Berg U . Widening of foot processes in normoalbuminuric adolescents with type 1 diabetes. Pediatr Nephrol. 2005; 20(6):750-8. DOI: 10.1007/s00467-005-1829-5. View

12.

Tsutsumi O, Sato M, Sato K, Mizuno M, Sakamoto S . Early prenatal diagnosis of inborn error of metabolism: a case report of a fetus affected with Fabry's disease. Asia Oceania J Obstet Gynaecol. 1985; 11(1):39-45. DOI: 10.1111/j.1447-0756.1985.tb00045.x. View

13.

Thurberg B, Rennke H, Colvin R, Dikman S, Gordon R, Collins A . Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002; 62(6):1933-46. DOI: 10.1046/j.1523-1755.2002.00675.x. View

14.

Banikazemi M, Bultas J, Waldek S, Wilcox W, Whitley C, McDonald M . Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2006; 146(2):77-86. DOI: 10.7326/0003-4819-146-2-200701160-00148. View

15.

Fogo A, Bostad L, Svarstad E, Cook W, Moll S, Barbey F . Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 2009; 25(7):2168-77. PMC: 2902894. DOI: 10.1093/ndt/gfp528. View

16.

Tondel C, Bostad L, Hirth A, Svarstad E . Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis. 2008; 51(5):767-76. DOI: 10.1053/j.ajkd.2007.12.032. View

17.

Macdermot K, Holmes A, Miners A . Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001; 38(11):750-60. PMC: 1734761. DOI: 10.1136/jmg.38.11.750. View

18.

Toyoda M, Najafian B, Kim Y, Caramori M, Mauer M . Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes. 2007; 56(8):2155-60. DOI: 10.2337/db07-0019. View

19.

Gubler M, Lenoir G, Grunfeld J, Ulmann A, Droz D, Habib R . Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int. 1978; 13(3):223-35. DOI: 10.1038/ki.1978.32. View

20.

Desnick R, Allen K, Desnick S, Raman M, BERNLOHR R, Krivit W . Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med. 1973; 81(2):157-71. View